Psycho-Babble Medication | about biological treatments | Framed
This thread | Show all | Post follow-up | Start new thread | List of forums | Search | FAQ

Re: Can someone explain this COVID/MAO-B study?

Posted by undopaminergic on June 20, 2020, at 5:53:55

In reply to Re: Can someone explain this COVID/MAO-B study?, posted by linkadge on June 19, 2020, at 15:01:00

> Great article and question.
> I've always been interested in MAO-B. Generally speaking, MAO-B activity is thought to increase with age. It also appears to be increased in depression (especially depression with cognitive disturbance). MAO-B inhibitors are used for Parkinson's disease, but also appear to have pro-cognitive effects (i.e. selegiline is approved for canine cognitive dysfunction).

What about rasagiline? It could be the (l-) amphetamine metabolites of selegiline.

PEA can most definitely have pro-cognitive effects, especially in ADHD, but I'm not sure this is true at physiological (natural) PEA levels, because my experience is with exogenous PEA and, on top of it, under MAO-B inhibition with selegiline.

> This study doesn't directly say whether MAO-B levels are elevated (or depressed) in patients with COVID associated delirium.

If that were so, I think the abstract would have stated that much. From what I read, it is about the differential concentrations in blood vs. CSF.





Post a new follow-up

Your message only Include above post

Notify the administrators

They will then review this post with the posting guidelines in mind.

To contact them about something other than this post, please use this form instead.


Start a new thread

Google www
Search options and examples
[amazon] for

This thread | Show all | Post follow-up | Start new thread | FAQ
Psycho-Babble Medication | Framed

poster:undopaminergic thread:1110832